GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion

US FDA Sets May 2023 Decision Date For RSV Vaccine

GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.

new gsk logo and hq
GSK could have its RSV vaccine on the US market by mid-2023 - but is likely to be accompanied by rival Pfizer. • Source: GSK

New chief scientific officer Tony Wood has said he is determined that GSK will take “smart risks” wherever opportunities present themselves – but has hinted that it will be “pragmatic” about expanding its presence in oncology.

Wood was speaking on his first call with analysts on the company’s 2 November third quarter business update, and set...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip